paclitaxel has been researched along with Benign Mastocytoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franciosi, AI; Guérios, SD; Pezzini, PC; Silva, DM | 1 |
| Akerlund-Denneberg, N; Bergvall, K; Kastengren Fröberg, G; Kessler, M; Persson, G; Rivera, P; Rowe, A; von Euler, H; Westberg, S; Willmann, M | 1 |
| Blay, J; Haeryfar, SM; Hoskin, DW; Morgan, M; Zhao, C | 1 |
1 trial(s) available for paclitaxel and Benign Mastocytoma
| Article | Year |
|---|---|
Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Dog Diseases; Dogs; Female; Infusions, Intravenous; Male; Mastocytoma; Paclitaxel; Prospective Studies; Quality of Life; Sweden; Treatment Outcome | 2013 |
2 other study(ies) available for paclitaxel and Benign Mastocytoma
| Article | Year |
|---|---|
Subcutaneous administration of paclitaxel in dogs with cancer: A preliminary study.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Lymphoma; Male; Mastocytoma; Paclitaxel; Sarcoma | 2015 |
Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody.
Topics: Animals; Antineoplastic Agents, Phytogenic; CD11a Antigen; CD3 Complex; Chromium Radioisotopes; Down-Regulation; Flow Cytometry; Immunotherapy; Intercellular Adhesion Molecule-1; Killer Cells, Natural; Mastocytoma; Mice; Mice, Inbred C57BL; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; Time Factors; Tumor Cells, Cultured; Vinblastine | 2003 |